[{"id":"2f9874c4-f677-4e33-b8c8-e0765095f8b3","acronym":"DUAL-OV-CAR-NK","url":"https://clinicaltrials.gov/study/NCT07480954","created_at":"2026-03-28T01:39:31.330Z","updated_at":"2026-03-28T01:39:31.330Z","phase":"Phase 1/2","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","source_id_and_acronym":"NCT07480954 - DUAL-OV-CAR-NK","lead_sponsor":"Beijing Biotech","biomarkers":" FOLR1 • MSLN • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MSLN • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 05/17/2028","study_completion_date":" 05/17/2028","last_update_posted":"2026-03-18"},{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"d7a65642-897e-45bd-94d5-4d6f95fb2fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856499","created_at":"2025-06-07T14:55:53.232Z","updated_at":"2025-06-07T14:55:53.232Z","phase":"Phase 1","brief_title":"Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT06856499","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cirtuvivint (SM08502)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-05-28"},{"id":"4d358bf9-7717-49a2-94ba-504711885d91","acronym":"PERSONA-Ovary","url":"https://clinicaltrials.gov/study/NCT06972693","created_at":"2025-09-07T01:36:12.539Z","updated_at":"2025-09-07T01:36:12.539Z","phase":"Phase 4","brief_title":"NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma","source_id_and_acronym":"NCT06972693 - PERSONA-Ovary","lead_sponsor":"European Institute of Oncology","biomarkers":" BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA2 • BRCA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 323","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-05-15"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"413aa90a-43b5-4d96-b8cc-5aee512ef199","acronym":"NRG-GY003","url":"https://clinicaltrials.gov/study/NCT02498600","created_at":"2021-01-18T12:02:53.906Z","updated_at":"2025-02-25T12:26:21.840Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02498600 - NRG-GY003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 09/05/2018","primary_completion_date":" 09/05/2018","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"65fa5200-d596-487d-929e-1fa05dc863a1","acronym":"NRG-GY007","url":"https://clinicaltrials.gov/study/NCT02713386","created_at":"2021-01-18T13:15:58.271Z","updated_at":"2025-02-25T12:26:27.453Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02713386 - NRG-GY007","lead_sponsor":"NRG Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA • CRP","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"9c52b3ba-74cb-41b4-9ef2-03d1ced908cf","acronym":"IMGN151-1001","url":"https://clinicaltrials.gov/study/NCT05527184","created_at":"2024-02-01T02:20:14.331Z","updated_at":"2025-02-25T12:28:59.108Z","phase":"Phase 1","brief_title":"First in Human Study of IMGN151 in Recurrent Gynaecological Cancers","source_id_and_acronym":"NCT05527184 - IMGN151-1001","lead_sponsor":"AbbVie","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opugotamig olatansine (IMGN-151)"],"overall_status":"Recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"8061a0a4-90b7-438d-bd01-079e025dc238","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113487","created_at":"2021-01-18T15:20:26.946Z","updated_at":"2025-02-25T14:01:16.153Z","phase":"Phase 2","brief_title":"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03113487","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation","tags":["PD-L1 • TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 08/26/2022","primary_completion_date":" 08/26/2022","study_txt":" Completion: 06/03/2025","study_completion_date":" 06/03/2025","last_update_posted":"2025-02-19"},{"id":"3b6e3d94-f722-44f3-897f-bf1317cea5d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672095","created_at":"2023-01-05T14:58:27.769Z","updated_at":"2025-02-25T14:09:21.750Z","phase":"Phase 1/2","brief_title":"Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT05672095","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA wild-type","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/18/2025","start_date":" 04/18/2025","primary_txt":" Primary completion: 11/27/2026","primary_completion_date":" 11/27/2026","study_txt":" Completion: 11/27/2026","study_completion_date":" 11/27/2026","last_update_posted":"2025-02-18"},{"id":"5634cce6-a08c-4073-971b-86089c97d96d","acronym":"CATALINA-2","url":"https://clinicaltrials.gov/study/NCT06690775","created_at":"2025-02-25T14:11:51.367Z","updated_at":"2025-02-25T14:11:51.367Z","phase":"Phase 2","brief_title":"CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","source_id_and_acronym":"NCT06690775 - CATALINA-2","lead_sponsor":"TORL Biotherapeutics, LLC","biomarkers":" CLDN6 • PROC","pipe":"","alterations":" ","tags":["CLDN6 • PROC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ixotatug vedotin (TORL-1-23) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 11/20/2024","start_date":" 11/20/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"0259c6da-60cc-4165-a7fc-adacc10727ab","acronym":"NCI-2018-00438","url":"https://clinicaltrials.gov/study/NCT03552471","created_at":"2021-01-18T17:29:09.671Z","updated_at":"2025-02-25T15:10:50.793Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03552471 - NCI-2018-00438","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 06/24/2022","primary_completion_date":" 06/24/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2025-02-13"},{"id":"527306d6-34b9-4ad0-b5f6-cf22600b56c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03968406","created_at":"2024-02-22T16:25:39.444Z","updated_at":"2025-02-25T15:11:11.864Z","phase":"Phase 1","brief_title":"Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers","source_id_and_acronym":"NCT03968406","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"aba0c228-f58a-4822-93bc-d017af087c85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887609","created_at":"2023-06-05T15:07:17.114Z","updated_at":"2025-02-25T15:13:30.894Z","phase":"Phase 2","brief_title":"An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib","source_id_and_acronym":"NCT05887609","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"e2d37db5-45cf-4e65-9db8-5800eea57b12","acronym":"HIPEC","url":"https://clinicaltrials.gov/study/NCT04415944","created_at":"2021-01-18T21:17:02.131Z","updated_at":"2025-02-25T15:18:39.353Z","phase":"Phase 2","brief_title":"Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy","source_id_and_acronym":"NCT04415944 - HIPEC","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-12"},{"id":"96f0f596-bee1-42fc-9dcc-41fcf8f78f40","acronym":"SL03-OHD-105","url":"https://clinicaltrials.gov/study/NCT05483933","created_at":"2022-08-02T12:55:49.417Z","updated_at":"2025-02-25T15:27:30.695Z","phase":"Phase 1","brief_title":"Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers","source_id_and_acronym":"NCT05483933 - SL03-OHD-105","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-11"},{"id":"a5404254-66c2-4fcb-a900-67628fac7462","acronym":"","url":"https://clinicaltrials.gov/study/NCT03296826","created_at":"2021-01-18T16:17:05.149Z","updated_at":"2025-02-25T15:25:39.354Z","phase":"","brief_title":"Prospective Cohort Study of Germline Variant Carriers with BRCA1 or BRCA2","source_id_and_acronym":"NCT03296826","lead_sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2032","primary_completion_date":" 03/31/2032","study_txt":" Completion: 03/31/2032","study_completion_date":" 03/31/2032","last_update_posted":"2025-02-11"},{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"cedde79c-686f-4afe-89d0-1fd3a8d96cf4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05200260","created_at":"2022-01-20T14:53:41.699Z","updated_at":"2025-02-25T14:38:18.943Z","phase":"Phase 2","brief_title":"Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","source_id_and_acronym":"NCT05200260","lead_sponsor":"Shanghai Gynecologic Oncology Group","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • docetaxel • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"cad13ffd-6e59-4a47-a0dc-e14e5025dcde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02884648","created_at":"2021-01-18T14:09:35.489Z","updated_at":"2025-02-25T16:30:59.280Z","phase":"Phase 2","brief_title":"Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery","source_id_and_acronym":"NCT02884648","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/15/2016","start_date":" 11/15/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-07"},{"id":"d42429d0-899b-4f9f-a9fd-c90fa6b9a50e","acronym":"NRG-GY027","url":"https://clinicaltrials.gov/study/NCT05276973","created_at":"2022-03-14T14:54:04.422Z","updated_at":"2025-02-25T16:38:53.900Z","phase":"Phase 1","brief_title":"Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05276973 - NRG-GY027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1","pipe":" | ","alterations":" HRD","tags":["PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-07"},{"id":"d44eaa90-9658-4ecd-acb1-1e96d85b2993","acronym":"FRAPPE","url":"https://clinicaltrials.gov/study/NCT05920798","created_at":"2023-06-27T14:08:13.033Z","updated_at":"2025-02-25T16:33:33.170Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT05920798 - FRAPPE","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-07"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"}]